Return to study ST001515 main page
MB Sample ID: SA127344
Local Sample ID: | FLHP-00166-01 |
Subject ID: | SU001589 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Select appropriate tab below to view additional metadata details:
Treatment:
Treatment ID: | TR001604 |
Treatment Summary: | Study subjects were admitted to the Clinical Research Unit (CRU) at the Translational Research Institute (TRI) at AdventHealth for 5 overnight stays. The first 2 overnight stays were used as baseline. On the 2nd day (Day -1), a baseline blood draw (-24 hours) was performed. On Day 1, a blood draw was again taken approximately 30 minutes prior to the start of the glucagon infusion. The study subjects began a ramped infusion (first 4 hours) of either saline (Placebo), Low Dose Glucagon (12.5ng/kg/min) or High Dose Glucagon (25ng/kg/min) for the next 72 hours (Inpatient). The Glucagon (GlucaGen, Novo Nordisk, Bagsværd Denmark) was administered under an FDA-approved IND (#136634). Intravenous (IV) bags of the study medication were hung together on an IV pole and changed out every 24 hours to provide a continuous infusion. With the exception of the 4-hour time point, all draws were performed in the overnight fasted state. |